These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 16638854)
1. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
3. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855 [TBL] [Abstract][Full Text] [Related]
4. [The value of searching for additional prognostic factors in combination with Nottingham Prognostic Index in breast carcinoma patients]. Jakić-Razumović J; Corić M; Vrbanec D; Babić D; Hlupić L; Belev B Lijec Vjesn; 2005; 127(1-2):3-7. PubMed ID: 16145866 [TBL] [Abstract][Full Text] [Related]
5. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390 [TBL] [Abstract][Full Text] [Related]
6. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334 [TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891 [TBL] [Abstract][Full Text] [Related]
8. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
9. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Rolland P; Spendlove I; Madjd Z; Rakha EA; Patel P; Ellis IO; Durrant L Int J Cancer; 2007 Mar; 120(6):1311-7. PubMed ID: 17187363 [TBL] [Abstract][Full Text] [Related]
10. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors. Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211 [TBL] [Abstract][Full Text] [Related]
11. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas. Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315 [TBL] [Abstract][Full Text] [Related]
13. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951 [TBL] [Abstract][Full Text] [Related]
14. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study]. Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497 [TBL] [Abstract][Full Text] [Related]
15. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748 [TBL] [Abstract][Full Text] [Related]
16. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546 [TBL] [Abstract][Full Text] [Related]
17. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. Sebastiani V; Botti C; Di Tondo U; Visca P; Pizzuti L; Santeusanio G; Alo PL Anticancer Res; 2006; 26(4B):2983-7. PubMed ID: 16886624 [TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334 [TBL] [Abstract][Full Text] [Related]
19. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors. Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]